Terazosin Oral Liquid Composition for Stable Dosing and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing terazosin hydrochloride formulations, particularly tablets and capsules, suffer from low bioavailability, absorption variability, and are difficult for elderly and dysphagic patients to swallow, leading to non-compliance and inaccurate dosing, especially in pediatric, geriatric, and hospitalized patients.
Innovation Solution
A stable oral liquid composition of terazosin hydrochloride is developed, comprising 0.5 to 5 mg/mL of terazosin or its pharmaceutically acceptable salt, with pH modifiers and excipients, maintaining a pH of 4.5 to 6.5, ensuring long-term stability and safety for oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If tablet or capsule forms of terazosin hydrochloride are used, then the dosage form is suitable for oral administration, but the disintegration time is long and dissolution rate is low, resulting in low bioavailability and absorption variability
Solution Approach 1:
The patent changes the physical state parameter from solid (tablet/capsule) to liquid formulation, which fundamentally alters dissolution characteristics. The liquid composition eliminates the disintegration step required for solid dosage forms, providing immediate availability of the drug in solution for absorption.
2Manufacturing precision
If tablet or capsule forms of terazosin hydrochloride are used, then the dosage form provides a fixed dose, but it is difficult for elderly and dysphagic patients to swallow, leading to non-compliance and inaccurate dosing
Solution Approach 1:
The patent changes the physical form parameter from solid to liquid, making the medication suitable for patients who cannot swallow tablets or capsules. The liquid formulation can be administered via spoon, syringe, or feeding tube, significantly improving ease of administration for elderly and dysphagic patients while maintaining dose accuracy through controlled concentration.
3Ease of operation
If liquid composition is developed for oral administration, then swallowability is improved for elderly and dysphagic patients, but stability of the composition must be maintained
Solution Approach 1:
The patent employs pH modifiers and excipients as intermediary substances to maintain the stability of terazosin hydrochloride in liquid formulation. These additives create a controlled chemical environment that prevents degradation of the active ingredient while preserving the liquid state for easy administration.
Solution Approach 2:
The patent controls the pH parameter of the liquid composition to ensure stability of terazosin hydrochloride. By maintaining the composition within a specific pH range, the patent prevents hydrolysis and other degradation reactions that would otherwise occur in aqueous liquid formulations.
Data Source
AI summary
A stable oral liquid composition of Terazosin and its pharmaceutically acceptable salt which is useful for treating symptomatic benign prostatic hyperplasia (BPH) and hypertension is disclosed. The oral liquid composition includes terazosin or a pharmaceutically acceptable salt thereof, at least one pH modifier, at least one pharmaceutically acceptable excipient, and a liquid vehicle.